Company Description
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States.
The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases.
In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid.
The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida.
Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jan 26, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 88 |
| CEO | Alexander G. Cumbo |
Contact Details
Address: 500 Rutherford Avenue, 3rd Floor Charlestown, Massachusetts 02129 United States | |
| Phone | 617-337-4680 |
| Website | solidbio.com |
Stock Details
| Ticker Symbol | SLDB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001707502 |
| CUSIP Number | 83422E105 |
| ISIN Number | US83422E2046 |
| Employer ID | 90-0943402 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ian F. Smith A.C.A., C.P.A. | Executive Chair |
| Alexander G. Cumbo | President, Chief Executive Officer and Director |
| Ilan Ganot | Co-founder, Strategic Advisor to the Chief Executive Officer and Director |
| David Tyronne Howton Jr., J.D. | Chief Operating Officer and Secretary |
| Gilad David Hayeem | Co-Founder |
| Annie Ganot | Co-Founder and Head of Patient Advocacy |
| Dr. Andrey Juan Zarur Ph.D. | Co-Founder |
| Kevin Tan C.F.A. | Chief Financial Officer and Treasurer |
| Stephen J. Di Palma M.B.A. | Treasurer and Principal Accounting Officer |
| Paul Herzich | Chief Technology Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 13, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 13, 2024 | 10-K | Annual Report |
| Feb 8, 2024 | EFFECT | Notice of Effectiveness |
| Feb 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 5, 2024 | UPLOAD | Filing |
| Jan 30, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |